“Governments on all continents have chosen to work together, not only to secure vaccines for their own people, but also to ensure that vaccines are available everywhere for the most vulnerable,” said Dr. Seth Berkley, CEO of Gavi. Although Pfizer`s vaccine has had logistical headaches for the Philippines, it has a strategic position in obtaining emergency approval by the FDA. The Trump administration is negotiating a deal to use its power to release stockpiles of raw materials to help Pfizer produce tens of millions of additional doses of its Covid 19 vaccine for Americans in the first half of next year, people familiar with the situation said. Thursday`s agreement with major pharmacy chains, food market pharmacies and other chains and networks includes about 3 out of 5 pharmacies in 50 U.S. states and territories such as Puerto Rico. It foresees a period next spring when unauthorized vaccines will be available beyond priority groups such as health care workers and retirement home residents. Since the beginning of the pandemic, President Rodrigo Duterte has repeatedly touted the need for a vaccine to save the country from COVID-19. If an agreement is reached, it could remedy, at least in part, an imminent defect that the administration itself probably helped create by not taking more doses of the vaccine developed by Pfizer with its German partner BioNTech. This summer, Pfizer agreed to deliver 100 million doses to the United States by the end of March, enough to vaccinate 50 million people, its vaccine requiring two shots. The arrangement was well-intentioned, but it became clear that additional screening layers could be harmful if not optimized for a highly competitive vaccine such as Pfizer and BioNTech. Asked why he signed the CDA three weeks after the OES took responsibility, Mr.
Duque said that there had been a definitive review of some of the contentious provisions, but that he had signed the agreement on the same day that he had consulted with Deputy Executive Secretary Michael Ong on the matter. June 29, 2020 – The DOH, through its pharmaceutical department, refers the proposal to the Philippine Science and Technology Council for Health Research and Development (DOST-PCHRD) as the leading agency for managing vaccine development for COVID 19 responses. A coalition of 156 countries has agreed on a “Landmark” agreement that allows for the rapid and equitable distribution of all new coronavirus vaccines to 3% of the population of participating countries, in order to protect vulnerable health systems, front-line medical personnel and front-line people in social institutions. “This is a mechanism that will allow for global coordination of deployment to maximize impact and help control the pandemic and ensure that the vaccine race is a competition,” he said. “With the commitments we announced today for the Covax plant, as well as our historic partnership with the industry, we now have a much better chance of ending the acute phase of this pandemic as soon as safe and effective vaccines become available.” Decisions on the distribution of vaccines that were initially provided under the regime remain at the discretion of individual nations, but he encouraged “countries to review these recommendations and be transparent about their decision-making processes and the final use of the vaccine.”